Rubraca Reimbursement Approved in Italy for Women With Relapsed Platinum-sensitive Ovarian Cancer
News
The Italian Medicines Agency (AIFA) has approved Clovis Oncology’s Rubraca (rucaparib) for reimbursement in Italy as a maintenance therapy for women with relapsed ovarian cancer who responded to platinum-based chemotherapy, ... Read more